# PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

> **NCT03507374** · EARLY_PHASE1 · TERMINATED · sponsor: **University of Utah** · enrollment: 20 (actual)

## Conditions studied

- Stroke
- Intracranial Atherosclerosis
- Intraplaque Hemorrhage

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03507374
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-30
- **Primary completion:** 2020-04-17
- **Final completion:** 2020-04-17
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Funding withdrawn
- **Last updated:** 2020-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03507374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03507374, "PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03507374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*